SUMMARY This study compares the gastroprotective effects of colloidal bismuth subcitrate (DeNol) with those of sucralfate and a methylated analogue of prostaglandin E2 (PGE2) against acute gastric lesions induced by acidified aspirin and absolute ethanol in rats. Both De-Nol and sucralfate given orally prevented dose dependently the formation of gastric lesions by these ulcerogens, DeNol being, respectively, twice and seven times more potent, on a weight basis, than sucralfate. As the gastroprotective activities of both De-Nol and sucralfate on ethanol lesions can be reversed by pretreatment with indomethacin and as De-Nol and sucralfate increase the mucosal generation and luminal release of PGE2, we postulate that mucosal prostaglandins may be involved in the mechanism of action of these drugs on the gastric mucosa.
of prostaglandins and to determine the influence of these agents on mucosal generation and release of prostaglandin.
Methods

GASTRIC SECRETORY STUDIES
The effect of De-Nol, sucralfate and methylated prostaglandin analogue on gastric secretion were studied in conscious rats prepared with a gastric fistula about one month earlier. They were fasted for about 24 hours and then placed in Bollman cages. The cannulas of the fistulas were opened and then the stomachs were washed out with saline. The basal gastric juice was collected for five 30 minute periods. After collecting three control 30 minute samples DeNol (80 mg/kg), sucralfate (400 mg/kg) or 16, 16 dimethyl PGE2 (10 ,ug/kg) dissolved in 1 ml water was introduced intragastrically for a 30 minute period, the gastric fistula being closed for 30 minutes. After this interruption the fistula was opened again, the stomach drained for five minutes and this collection discarded. The collection was continued for two 30 minute periods with saline infused sc at a rate of 4 ml/h throughout. Acid and pepsin secretion was measured in each 30 minute sample as described '5 and expressed as outputs/60 minute period after 201 administration of tested drugs or 1 ml of water (control). All secretory tests were done on the same 10 gastric fistula rats weighing about 250 g.
PRODUCTION OF GASTRIC MUCOSAL LESIONS
Acute gastric ulcerations were induced in Wistar rats (180-200 g bw) by intragastric administration of absolute ethanol or acidified ASA.
Absolute ethanol was administered in 24 hour fasted rats in a volume of 1 ml using a metal orogastric tube.'6 One hour later the animals were killed by a blow to the head, the stomach was removed and the number and area of gastric necrotic lesions were measured planimetrically (Morphomat, Carl Zeiss, Berlin, Germany).
Acidified aspirin was administered in 24 hour fasted rats in a bolus dose of 60 mg/kg followed by a dose of 42 mg/kg/h for a three hour period. Aspirin was dissolved in 0-15 M HCl and instilled intragastrically (through a plastic tube inserted surgically) into the stomach two hours before the start of the experiment as previously described.'57 After three hours of aspirin administration, the animals were killed and the area of all gastric ulcerations was measured planimetrically.
De-Nol (gift from Dr D W R Hall, Medical Department, Gist-brocades, Delft, The Netherlands) was dissolved in water and administered po in doses ranging from 2.5-80 mg/kg about 30 minutes before the start of the administration of absolute ethanol or acidified aspirin. Sucralfate (gift from Dr E Gehrls, E Merck, Darmstadt, GFR) was suspended in water and used in doses ranging from 12.5-400 mg/kg. For comparison, 16,16 dimethyl PGE2 (gift from Dr J Pike, The Upjohn Co, Kalamazoo, Michigan) was used po in a standard protective doses (10 rig/kg).
MEASUREMENT OF MUCOSAL GENERATION OF PROSTAGLANDIN
The role of endogenous prostaglandin in the protection by De-Nol and sucralfate was examined in two ways: (1) by reversal of their gastroprotective effects by pretreatment with indomethacin (5 mg/kg po) and (2) by directly measuring mucosal generation and luminal release of PGE2 using radioimmunoassay of PGE2. Immediately after killing the animals, the abdomen was opened and the stomach was clamped at the cardia and the pylorus. One millilitre of saline was then injected into the stomach and its contents collected for the measurement of luminal release of PGE2 using commercially available kits (New England Nuclear NEN, Dreieich, Germany). A large biopsy (about 50 mg) of the fundic mucosa was then obtained to determine the capability of the mucosa to generate PGE2 as previously described.5 17 All experiments were carried out on Wistar rats Table 2 . Indomethacin given po in a dose of 5 mg/kg failed to affect the integrity of the gastric mucosa. De-Nol in a dose of 40 mg/kg showed usual protection against absolute ethanol and this was almost completely reversed by the pretreatment with indomethacin given ig 90 minutes before the combination of De-Nol and ethanol. In similar studies with sucralfate, used in a dose 100 mg/kg, the reversal of the protection by indomethacin with respect to the area and number of ethanol lesions was not significantly different from that obtained with De-Nol ( Table 2 ).
This study shows that De-Nol is effective in the prevention of the formation of acute gastric ulcerations induced by acidified aspirin and in the protection of gastric mucosa against acute necrotic lesions caused by absolute ethanol.
As in previous studies,'2 we found that the antiulcer action of De-Nol against various ulcerogens is dose-dependent and similar to that of sucralfate but occurs at lower doses than sucralfate. This indicates that De-Nol is several times more potent on a weight basis than sucralfate, a standard anti-ulcer drug. Because aspirin induced mucosal lesions depend on gastric acid secretion and can be prevented by potent inhibitors of this secretion such as ranitidine" additional secretory tests were done to find out what effect, if any, De-Nol and sucralfate had on gastric acid secretion. It was found that both acid and pepsin secretions were similar in the vehicle and De-Nol or sucralfate treated rats. Thus, we exclude the mediation of decreased gastric acid secretion in the antiulcer effect of De-Nol or sucralfate.
This study shows for the first time that De-Nol, like sucralfate'2 is highly effective in the protection of gastric mucosa against acute necrosis induced by corrosive substances such as absolute ethanol. Although De-Nol produced a similar onset and duration of reduction of ethanol lesions as sucralfate, the dose of CBS was about 10 times lower. As this protection can be reversed by indomethacin, a potent inhibitor of prostaglandin biosynthesis, it may be assumed that mucosal prostaglandin are implicated. Direct support for this assumption was obtained from the studies with mucosal generation and luminal release of prostaglandin. Our study showed that both De-Nol and sucralfate administered into the intact stomach caused a dose-dependent increase in the ability of the fundic mucosa to generate PGE2 and in the release of this prostaglandin into the gastric lumen. It is likely that prostaglandin formed in large amounts account for the effects observed after DeNol or sucralfate including stimulation of mucusalkaline secretion, tighbening the mucosal barrier3 and the increase in the mucosal resistance and mucosal cell renewal. 12 The mediation by endogenous prostaglandin in the gastroprotective activities of sucralfate was previously proposed.'2 The present study provides evidence that De-Nol also protects the gastric mucosa through increased biosynthesis of endogenous prostaglandin.
Both De-Nol and sucralfate have been shown to exhibit high efficacy not only in healing of gastroduodenal ulcerations but also in reducing the ulcer relapse rate. ' 
